The role of gut bacteria in pancreatic cancer development and progression
Microbial Dysbiosis in Pancreatic Cancer Initiation and Progression
This study is looking at how changes in gut bacteria might affect the development and growth of pancreatic cancer, and it’s inviting patients to help by sharing samples or information to better understand how these bacteria interact with tumors and could lead to better treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10893577 on NIH RePORTER |
What this research studies
This research investigates how changes in gut bacteria, known as microbial dysbiosis, may influence the initiation and progression of pancreatic cancer. By examining the unique microbiome present in pancreatic tumors, the study aims to uncover the mechanisms through which these bacteria affect immune responses and tumor growth. The researchers will explore how pathogenic bacteria interact with pancreatic cells and alter the tumor microenvironment, potentially leading to more effective treatments. Patients may be involved in providing samples or data to help understand these interactions better.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer or those at high risk for developing the disease.
Not a fit: Patients with non-cancerous conditions or those not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve survival rates for pancreatic cancer patients.
How similar studies have performed: Other research has shown promising results in understanding the role of microbiomes in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Daley, Donnele — University of Michigan at Ann Arbor
- Study coordinator: Daley, Donnele
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.